Parkman Healthcare Partners’s Altimmune ALT Stock Holding History

Parkman Healthcare Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-559,755	Closed	-$6.55M	–	91
2022 Q2	$6.55M	Buy	559,755 +250,169	+81%	+$1.54M	2.41%	13
2022 Q1	$1.89M	Buy	309,586 +46,112	+18%	+$340K	0.55%	49
2021 Q4	$2.41M	Buy	263,474 +88,474	+51%	+$940K	0.53%	52
2021 Q3	$1.98M	Sell	175,000 -25,000	-13%	-$304K	0.5%	54
2021 Q2	$1.97M	Buy	+200,000	New	+$2.73M	0.43%	58
2021 Q1	–	Sell	-100,000	Closed	-$1.13M	–	85
2020 Q4	$1.13M	Buy	+100,000	New	+$1.18M	0.29%	74

Other funds holding ALT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parkman Healthcare Partners's ALT Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Altimmune (ALT) in Q3 2022, closing a stake of 559,755 shares — an estimated $6.55M sold.

Parkman Healthcare Partners first reported a position in ALT in Q4 2020 and held it in 6 quarters. The position peaked at $6.55M in Q2 2022. 122 funds tracked by Wall St. Rank hold ALT as of Q3 2022.

Parkman Healthcare Partners reported no remaining Altimmune position as of Q3 2022 after selling out during the quarter.
Parkman Healthcare Partners sold 559,755 Altimmune shares in Q3 2022, an estimated $6.55M.
Parkman Healthcare Partners first reported a position in Altimmune in Q4 2020 and held it in 6 quarters.
Parkman Healthcare Partners's Altimmune position peaked at $6.55M in Q2 2022.
122 funds tracked by Wall St. Rank held Altimmune as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.